These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 34160188)
1. Therapy in elderly IBD patients. Castiglione F; Imperatore N; Zingone F; D'Incà R Minerva Gastroenterol (Torino); 2024 Mar; 70(1):89-97. PubMed ID: 34160188 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study. Pugliese D; Privitera G; Crispino F; Mezzina N; Castiglione F; Fiorino G; Laterza L; Viola A; Bertani L; Caprioli F; Cappello M; Barberio B; Ricci C; Balestrieri P; Daperno M; Pluchino D; Rizzello F; Scribano ML; Sablich R; Pastorelli L; Manguso F; Variola A; Di Sario A; Grossi L; Armuzzi A; Aliment Pharmacol Ther; 2022 Jul; 56(1):95-109. PubMed ID: 35876062 [TBL] [Abstract][Full Text] [Related]
3. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements. Mader O; Juillerat P; Biedermann L; Michetti P; Hruz P; Pittet V; Rogler G; Zahnd-Straumann N; Seibold F United European Gastroenterol J; 2021 Apr; 9(3):398-406. PubMed ID: 33203339 [TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn's disease in patients with prior failure of anti-tumour necrosis factor treatment. Hyun HK; Zhang HS; Yu J; Kang EA; Park J; Park SJ; Park JJ; Kim TI; Kim WH; Cheon JH BMC Gastroenterol; 2022 Mar; 22(1):143. PubMed ID: 35346063 [TBL] [Abstract][Full Text] [Related]
6. Comparing persistence of new biologics to conventional anti-TNF alphas in adult patients with inflammatory bowel disease: a systematic review and meta-analysis protocol. Yiu TH; Ko Y; Pudipeddi A; Natale P; Leong RW BMJ Open; 2023 Oct; 13(10):e073071. PubMed ID: 37788929 [TBL] [Abstract][Full Text] [Related]
7. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study. Garcia-Romero R; Martinez de Zabarte Fernandez JM; Pujol-Muncunill G; Donat-Aliaga E; Segarra-Cantón O; Irastorza-Terradillos I; Medina-Benitez E; Ruiz-Hernández CJ; Carrillo-Palau M; Ros-Arnal I; Rodriguez-Martínez A; Escartin-Madurga L; Gutiérrez-Junquera C; Vicente-Santamaría S; Velasco Rodriguez-Belvis M; Fernández-Fernández S; Alberto-Alonso JR; Montraveta M; Torres-Peral R; Navalon-Rubio M; Navas-López VM; Martin de Carpi J Eur J Pediatr; 2021 Sep; 180(9):3029-3038. PubMed ID: 33880650 [TBL] [Abstract][Full Text] [Related]
8. Perception and clinical decisions from inflammatory bowel diseases' specialists towards positioning of new therapies in Crohn's disease and ulcerative colitis: A national web-based survey from the Brazilian IBD study group (GEDIIB). Romero RK; Magro DO; Queiroz NSF; Damião AOMC; Teixeira FV; Nones RB; Sassaki LY; Saad-Hossne R; Kotze PG Gastroenterol Hepatol; 2022; 45(7):499-506. PubMed ID: 34634427 [TBL] [Abstract][Full Text] [Related]
9. Ustekinumab and Vedolizumab Are Equally Safe and Effective in Elderly Crohn's Disease Patients. Gebeyehu GG; Fiske J; Liu E; Limdi JK; Broglio G; Selinger C; Razsanskaite V; Smith PJ; Flanagan PK; Subramanian S Dig Dis Sci; 2023 May; 68(5):1983-1994. PubMed ID: 36436155 [TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis. Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Guardiola J; Jahnsen J; Lees C; Louis E; Lukáš M; Reinisch W; Roblin X; Jang M; Byun HG; Kim DH; Lee SJ; Atreya R BMC Gastroenterol; 2022 Jun; 22(1):291. PubMed ID: 35676620 [TBL] [Abstract][Full Text] [Related]
12. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. Wang Y; Wang J; Pekow J; Dalal S; Cohen RD; Ollech J; Israel A; Shogan BD; Micic D; Cannon L; Umanskiy K; Hurst R; Hyman N; Rubin DT; Sakuraba A J Gastroenterol Hepatol; 2019 Dec; 34(12):2090-2095. PubMed ID: 31169926 [TBL] [Abstract][Full Text] [Related]
13. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study. Targownik LE; Benchimol EI; Bernstein CN; Singh H; Lix L; Tennakoon A; Leung S; Aviña A; Coward S; Jones J; Kaplan G; Murthy SK; Nguyen GC; Peña-Sánchez JN Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1788-1798.e2. PubMed ID: 30448599 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness and Safety of Ustekinumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Honap S; Meade S; Ibraheim H; Irving PM; Jones MP; Samaan MA Dig Dis Sci; 2022 Mar; 67(3):1018-1035. PubMed ID: 33723700 [TBL] [Abstract][Full Text] [Related]
15. Comparison of outcomes of continuation/discontinuation of 5-aminosalicylic acid after initiation of anti-tumor necrosis factor-alpha therapy in patients with inflammatory bowel disease. Choi YI; Kim TJ; Park DK; Chung JW; Kim KO; Kwon KA; Kim YJ Int J Colorectal Dis; 2019 Oct; 34(10):1713-1721. PubMed ID: 31471699 [TBL] [Abstract][Full Text] [Related]
17. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review. Damião AOMC; de Azevedo MFC; Carlos AS; Wada MY; Silva TVM; Feitosa FC World J Gastroenterol; 2019 Mar; 25(9):1142-1157. PubMed ID: 30863001 [TBL] [Abstract][Full Text] [Related]
18. Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD Patients. Verstockt B; Mertens E; Dreesen E; Outtier A; Noman M; Tops S; Schops G; Van Assche G; Vermeire S; Gils A; Ferrante M J Crohns Colitis; 2020 Mar; 14(3):332-341. PubMed ID: 31504343 [TBL] [Abstract][Full Text] [Related]
19. Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study. Ko Y; Paramsothy S; Yau Y; Leong RW Aliment Pharmacol Ther; 2021 Aug; 54(3):292-301. PubMed ID: 34151447 [TBL] [Abstract][Full Text] [Related]